SCHEMBL13197894

SCHEMBL13197894

CCN(CC)C(=O)CNC(=O)c1nc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cn1CC=C(Cl)Cl

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.45
PRMT3 O60678 1/20 0.40
MAPT P10636 1/20 0.40
EPHX2 P34913 6/20 0.40
RAF1 P04049 1/20 0.37
IGF1R P08069 1/20 0.37
FAAH O00519 1/20 0.36
POLB P06746 1/20 0.36
KDM4E B2RXH2 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 1/20 0.36
EPHB4 P54760 1/20 0.36
TEK Q02763 1/20 0.36
ABL1 P00519 1/20 0.36
SCN9A Q15858 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13197874 0.86 MCHR1 (0.47) MCHR1PRMT3MAPTEPHX2RAF1
SCHEMBL13197827 0.85 MCHR1 (0.44) MCHR1MAPTEPHX2RAF1IGF1R
SCHEMBL13197829 0.84 MCHR1 (0.43) MCHR1MAPTEPHX2IGF1RFAAH
SCHEMBL13197825 0.83 EPHX2 (0.44) MCHR1EPHX2
SCHEMBL2876477 0.83 EPHX2 (0.49) MCHR1EPHX2IGF1RFAAHEPHB4
SCHEMBL13197893 0.82 EPHX2 (0.40) MCHR1MAPTEPHX2RAF1IGF1R
SCHEMBL13197886 0.82 MCHR1 (0.41) MCHR1MAPTEPHX2RAF1IGF1R
SCHEMBL13197831 0.81 EPHX2 (0.42) MCHR1MAPTEPHX2RAF1IGF1R
SCHEMBL13197887 0.81 MCHR1 (0.42) MCHR1MAPTEPHX2IGF1RKDM4E
SCHEMBL13197828 0.80 CYP1A2 (0.45) MCHR1MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 MCHR1 4719/4885PRMT3 553/4885MAPT 3312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.